Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.07
+0.22 (3.76%)
At close: Sep 21, 2026, 4:00 PM EDT
6.00
-0.07 (-1.15%)
After-hours: Sep 21, 2026, 7:39 PM EDT
Nuvation Bio Revenue
Nuvation Bio had revenue of $31.69M in the quarter ending June 30, 2026, with 555.64% growth. This brings the company's revenue in the last twelve months to $169.90M, up 1,083.56% year-over-year. In the year 2025, Nuvation Bio had annual revenue of $62.90M with 698.96% growth.
Revenue (ttm)
$169.90M
Revenue Growth
+1,083.56%
P/S Ratio
12.54
Revenue / Employee
$557,049
Employees
305
Market Cap
2.13B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 62.90M | 55.03M | 698.96% |
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 1.97B |
| ADMA Biologics | 512.28M |
| Vericel | 306.30M |
| UroGen Pharma | 188.73M |
| Mesoblast | 120.25M |
| Agios Pharmaceuticals | 98.34M |
| Recursion Pharmaceuticals | 54.86M |
| Zenas BioPharma | 1.00M |
NUVB News
- 4 days ago - Nuvation Bio announces FDA approval of sNDA for Ibtrozi - TheFly
- 4 days ago - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PRNewsWire
- 6 days ago - Nuvation Bio’s Ibtrozi shows durable efficacy in NSCLC studies - TheFly
- 6 days ago - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PRNewsWire
- 11 days ago - Nuvation Bio Transcript: Cantor Global Healthcare Conference - Transcripts
- 12 days ago - Nuvation Bio Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 19 days ago - Nuvation Bio to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 weeks ago - Nuvation Bio initiated with an Overweight at Cantor Fitzgerald - TheFly